The Oncology Institute, Inc.
TOI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 21.3% | 28.4% | 24.4% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 13.7% | 18.4% | 20.6% | 20.1% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -15.3% | -23.8% | -32.5% | -22.6% |
| Other Income/Exp. Net | -$0 | -$0 | $0 | $0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | -$0 |
| Tax Expense | $0 | -$0 | -$0 | -$0 |
| Net Income | -$0 | -$0 | $0 | -$0 |
| % Margin | -16.4% | -25.6% | 0.1% | -5.4% |
| EPS | -0.71 | -0.92 | 0.001 | -0.16 |
| % Growth | 22.8% | -102,322.2% | 100.6% | – |
| EPS Diluted | -0.71 | -0.92 | -0.21 | -0.16 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -13.7% | -16.7% | -26.8% | -20.7% |